As the treatment efficacy of ICIs in gastric and oesophageal cancer is limited, biomarkers for ICI treatment have been investigated intensively, including PD-L1 expression, microsatellite instability, tumour mutation burden, and Epstein-Barr virus infection [28]. The gene discussed is CD274; the disease is Epstein-Barr virus infection.